Johnson & Johnson to buy Ambrx in $2B deal

By Becker's Hospital Review - Healthcare News in Becker's Hospital Review, Channels, Featured, ROOT, Static
January 8, 2024

Johnson & Johnson plans to acquire Ambrx, a clinical-stage biotechnology company developing cancer treatments, for $1.9 billion.

Read the full post on Becker's Hospital Review - Healthcare News

Becker's Hospital Review - Healthcare News